State of the art in therapeutic drug monitoring

Elena Llorente Fernandez, Laura Parés, Iratxe Ajuria, Fernando Bandres, Bartomeu Castanyer, Francesc Campos, Carme Farré, Leonor Pou, Josep Maria Queraltó, Jordi To-Figueras

Research output: Contribution to journalReview articleResearchpeer-review

16 Citations (Scopus)


Therapeutic drug monitoring (TDM) is a multidisciplinary activity. Because laboratory reports are part of the patient's chart, some clinical information is required. In order to guarantee quality and safety, an increasing number of TDM departments have implemented a quality management system. The aim of the present article is to review the three phases of TDM: the pre-analytical, analytical and post-analytical phases. In the pre-analytical phase, it is necessary to acquire a valid specimen collected at the specific time window. Analytical methods should be validated, assessing possible interfering substances. The objective of the post-analytical phase is the final report, which should include correct interpretation, as well as possible advice. Appropriate pharmacokinetic interpretation avoids unnecessary costs and leads to clinical benefits. © 2010 by Walter de Gruyter Berlin New York.
Original languageEnglish
Pages (from-to)437-446
JournalClinical Chemistry and Laboratory Medicine
Issue number4
Publication statusPublished - 1 Apr 2010


  • Analytical phase
  • Post-analytical phase
  • Pre-analytical phase
  • Quality management system
  • Therapeutic drug monitoring


Dive into the research topics of 'State of the art in therapeutic drug monitoring'. Together they form a unique fingerprint.

Cite this